[125I]CPCR4.3作为体外和体内灵敏特异检测hCXCR4和mCXCR4表达的研究工具的验证
该研究评估了[125I]CPCR4.3作为临床前工具,用于体外和体内靶向人源(hCXCR4)和鼠源(mCXCR4)CXCR4的有效性。与[68Ga]Pentixafor相比,[125I]CPCR4.3对多种人癌细胞系显示出2.4至11倍增加的特异性结合,并对表达mCXCR4的细胞有强且高度特异的结合,而[68Ga]Pentixafor无法检测到后者。其原因是碘代CPCR4对hCXCR4和mCXCR4具有同等高亲和力(IC50分别为5.4±1.5和4.9±1.7 nM),而[natGa]Pentixafor的亲和力较低(hCXCR4: 42.4±11.6 nM,mCXCR4: >1000 nM)。[125I]CPCR4.3还显示出增强的示踪剂内化(较参照物高1.5-2倍)。在免疫健全Black Six和免疫缺陷CD-1裸鼠的体内生物分布研究中,[125I]CPCR4.3主要经肝胆排泄(logP=0.51),导致肝脏和肠道放射性高;但在内源性表达mCXCR4的器官(脾、肺、肾上腺)中,即使受体表达水平低,也显示出高且特异的聚集。结论认为,[125I]CPCR4.3是灵敏可靠的物种非依赖性CXCR4表达定量工具,但其清除特性欠佳限制了其用于123I(SPECT)或124I(PET)的体内显像;然而,由于其在高表达mCXCR4组织中的高特异聚集,有望作为强大的临床前工具,通过生物分布和放射自显影等研究各种小鼠疾病模型中CXCR4的参与和动力学。
要点
- [125I]CPCR4.3对hCXCR4和mCXCR4均有高亲和力(IC50≈5 nM),而[68Ga]Pentixafor对mCXCR4亲和力极低(>1000 nM)。
- 体外结合实验显示[125I]CPCR4.3较[68Ga]Pentixafor特异性结合提高2.4-11倍,且内化增强1.5-2倍。
- 体内主要经肝胆排泄,但在脾、肺、肾上腺等mCXCR4表达器官中高且特异聚集。
核心结论
- [125I]CPCR4.3是一种灵敏可靠的物种非依赖性CXCR4表达定量临床前工具。
- 其清除特性欠佳限制其用于123I或124I的体内显像应用。
- 由于其在高表达mCXCR4组织中的高特异聚集,有望用于小鼠疾病模型的生物分布和放射自显影研究。
研究设计与样本
- 体外研究比较[125I]CPCR4.3与[68Ga]Pentixafor对多种人癌细胞系(Jurkat、Daudi、HT-29、SH-5YSY、MCF-7、LNCaP)和mCXCR4表达细胞(mCXCR4转染CHO、Eμ-myc 1080、4T1)的结合特性。
- 测定碘代CPCR4与[natGa]Pentixafor对hCXCR4和mCXCR4的亲和力(IC50)。
- 在免疫健全Black Six和免疫缺陷CD-1裸鼠中进行体内生物分布研究。
主要发现
- [125I]CPCR4.3对hCXCR4表达癌细胞系的特异性结合较[68Ga]Pentixafor提高2.4-11倍。
- [125I]CPCR4.3对mCXCR4表达细胞显示强且高度特异性结合,而[68Ga]Pentixafor无法检测到。
- 碘代CPCR4对hCXCR4和mCXCR4的IC50分别为5.4±1.5和4.9±1.7 nM;[natGa]Pentixafor分别为42.4±11.6 nM和>1000 nM。
- [125I]CPCR4.3的内化较参照物增强1.5-2倍。
- 体内主要经肝胆排泄(logP=0.51),导致肝脏和肠道放射性高;在脾、肺、肾上腺中高且特异聚集。
关键数值与推荐
- 碘代CPCR4对hCXCR4的IC50=5.4±1.5 nM,对mCXCR4的IC50=4.9±1.7 nM。
- [natGa]Pentixafor对hCXCR4的IC50=42.4±11.6 nM,对mCXCR4的IC50>1000 nM。
- [125I]CPCR4.3的logP=0.51。
- [125I]CPCR4.3特异性结合较[68Ga]Pentixafor提高2.4-11倍(人癌细胞系)。
- [125I]CPCR4.3内化较参照物增强1.5-2倍。
临床怎么用
- [125I]CPCR4.3可用于临床前研究中灵敏特异地检测和定量hCXCR4及mCXCR4表达。
- 适用于小鼠疾病模型的生物分布和放射自显影研究,以探究CXCR4的参与和动力学。
- 因清除特性欠佳,不推荐用于123I(SPECT)或124I(PET)的体内显像应用。
局限性
- [125I]CPCR4.3的清除特性欠佳(主要经肝胆排泄,logP=0.51),限制其用于123I或124I的体内显像。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The development and clinical translation of [68Ga] Pentixafor has substantially promoted the relevance of non-invasive PET imaging of CXCR4 expression in a broad spectrum of diseases, including cancer and inflammation. Its pronounced selectivity for the human receptor (hCXCR4), however, precludes the use of [68Ga] Pentixafor for imaging receptor expression and dynamics in CXCR4-related diseases in endogenous mouse models. To overcome this restriction, [125I]CPCR4.3, a structurally related pentapeptide ligand, has been evaluated as a preclinical tool for efficient in vitro and in vivo targeting of hCXCR4 and mCXCR4. RESULTS: Compared to the reference [68Ga] Pentixafor, [125I]CPCR4.3 showed 2.4- to 11-fold increased specific binding to human cancer cell lines with different hCXCR4 expression levels (Jurkat, Daudi, HT-29, SH-5YSY, MCF-7, LNCaP) as well as strong and highly specific binding to mCXCR4 expressing cells (mCXCR4-transfected CHO cells, Eμ-myc 1080, 4 T1), which was not detectable for [68Ga]Pentixafor. This is the consequence of the equally high affinity of iodo-CPCR4 to hCXCR4 and mCXCR4 (IC50 = 5.4 ± 1.5 and 4.9 ± 1.7 nM, respectively) as opposed to [natGa] Pentixafor (hCXCR4: 42.4 ± 11.6 nM, mCXCR4: > 1000 nM). Additionally, [125I]CPCR4.3 showed enhanced tracer internalization (factor of 1.5-2 compared to the reference). In vivo biodistribution studies in immunocompetent Black Six and immunocompromised CD-1 nude mice showed predominant hepatobiliary excretion of [125I]CPCR4.3 (logP = 0.51), leading to high activity levels in liver and intestines. However, [125I]CPCR4.3 also showed high and specific accumulation in organs with endogenous mCXCR4 expression (spleen, lung, adrenals), even at low receptor expression levels. CONCLUSIONS: Due to its excellent hCXCR4 and mCXCR4 targeting efficiency, both in vitro and in vivo, [125I]CPCR4.3 represents a sensitive and reliable tool for the species-independent quantification of CXCR4 expression. Its suboptimal clearance properties will certainly restrict its use for in vivo imaging applications using 123I (for SPECT) or 124I (for PET), but due to its high and specific accumulation in mCXCR4 expressing tissues, [125I]CPCR4.3 holds promise as a powerful preclinical tool for the investigation and quantification of CXCR4 involvement and kinetics in various murine disease models via, e.g., biodistribution and autoradiography studies.
引用
- Schottelius M, Ludescher M, Richter F, et al. Validation of [125I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo. EJNMMI Res. 2019. PMID: 31410585. doi:10.1186/s13550-019-0545-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。